BAO PHARMA-B (02659) Proposes H-Share Full Circulation Plan

Stock News2025-12-30

BAO PHARMA-B (02659) announced that on December 30, 2025, the company submitted filing materials to the China Securities Regulatory Commission for its proposed H-share full circulation plan. The initiative aims to convert a total of 63.1163 million unlisted shares into H-shares, representing approximately 19.36% of the company's total issued share capital as of the announcement date. Following receipt of all required approvals—including the filing notice from the CSRC and the approval from the Stock Exchange—and compliance with all applicable laws, regulations, and rules, these unlisted shares will be converted into H-shares. The company will then apply for approval to list and trade these H-shares on the Main Board of the Stock Exchange. In accordance with the company's articles of association, no separate shareholders' meeting is required to approve the conversion and listing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182770095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182770095","market":"us","top_or_hot":-1,"title":"BAO PHARMA-B (02659) Proposes H-Share Full Circulation Plan","media":"Stock News","content":"<p>BAO PHARMA-B (02659) announced that on December 30, 2025, the company submitted filing materials to the China Securities Regulatory Commission for its proposed H-share full circulation plan. The initiative aims to convert a total of 63.1163 million unlisted shares into H-shares, representing approximately 19.36% of the company's total issued share capital as of the announcement date. Following receipt of all required approvals—including the filing notice from the CSRC and the approval from the Stock Exchange—and compliance with all applicable laws, regulations, and rules, these unlisted shares will be converted into H-shares. The company will then apply for approval to list and trade these H-shares on the Main Board of the Stock Exchange. In accordance with the company's articles of association, no separate shareholders' meeting is required to approve the conversion and listing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B (02659) Proposes H-Share Full Circulation Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B (02659) Proposes H-Share Full Circulation Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-30 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B (02659) announced that on December 30, 2025, the company submitted filing materials to the China Securities Regulatory Commission for its proposed H-share full circulation plan. The initiative aims to convert a total of 63.1163 million unlisted shares into H-shares, representing approximately 19.36% of the company's total issued share capital as of the announcement date. Following receipt of all required approvals—including the filing notice from the CSRC and the approval from the Stock Exchange—and compliance with all applicable laws, regulations, and rules, these unlisted shares will be converted into H-shares. The company will then apply for approval to list and trade these H-shares on the Main Board of the Stock Exchange. In accordance with the company's articles of association, no separate shareholders' meeting is required to approve the conversion and listing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1182770095","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182770095","pubTimestamp":1767085831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAO PHARMA-B (02659) announced that on December 30, 2025, the company submitted filing materials to the China Securities Regulatory Commission for its proposed H-share full circulation plan. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B","BK1161":"生物科技"},"translate_title":"宝药业-B(02659)提出H股全流通方案","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"BAO PHARMA-B (02659) announced that on December 30, 2025, the company submitted filing materials to the China Securities Regulatory Commission for its proposed H-share full circulation plan. The initiative aims to convert a total of 63.1163 million unlisted shares into H-shares, representing approximately 19.36% of the company's total issued share capital as of the announcement date. Following receipt of all required approvals—including the filing notice from the CSRC and the approval from the Stock Exchange—and compliance with all applicable laws, regulations, and rules, these unlisted shares will be converted into H-shares. The company will then apply for approval to list and trade these H-shares on the Main Board of the Stock Exchange. In accordance with the company's articles of association, no separate shareholders' meeting is required to approve the conversion and listing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182770095","isCrawlerRequest":true}